SLN
Silence Therapeutics plc
NASDAQ · GBHealthcareBiotechnology
$10.49-0.10%
Price as of Jul 20, 2026
SLN growth
Silence Therapeutics plc growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- -96.5%
- EBITDA
- -14.7%
- EBIT
- -7.3%
- EPS
- -4.3%
- Free cash flow
- -5.2%
- Operating cash flow
- -5.3%
Forward estimates
- Revenue
- +670.7%
- EBITDA
- +90.9%
- EPS
- +87.2%
Three-year CAGR
- Revenue
- -68.4%
- EBITDA
- -79.7%
- EBIT
- -41.7%
- Net income
- -95.6%
- EPS
- +20.3%
- Free cash flow
- -15.0%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.